Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16049014 | 0.85 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL16053770 | 0.84 | AOC3 (0.78) | AOC3KCNH2 | |
| SCHEMBL16047574 | 0.84 | AOC3 (0.93) | AOC3KCNH2 | |
| Hydrochloric Acid SCHEMBL16048739 | 0.83 | AOC3 (0.77) | AOC3KCNH2 | |
| SCHEMBL16049436 | 0.81 | AOC3 (1.00) | AOC3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL21931202 | 0.79 | AOC3 (0.77) | AOC3KCNH2 | |
| SCHEMBL25765426 | 0.77 | AOC3 (0.79) | AOC3KCNH2 | |
| SCHEMBL16049471 | 0.77 | AOC3 (0.78) | AOC3KCNH2 | |
| SCHEMBL20924301 | 0.75 | AOC3 (0.79) | AOC3KCNH2 | |
| SCHEMBL25764999 | 0.75 | AOC3 (0.79) | AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | Benevolentai Cambridge Limited (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | AOC3 55/4885KCNH2 1764/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | AOC3 21/4885KCNH2 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.